Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are first-line treatments for advanced non-small cell lung cancer (NSCLC).
• Acquired EGFR mutations are a primary cause of resistance to EGFR TKIs.
• Third-generation EGFR TKIs like osimertinib (Tagrisso) are approved but eventually face resistance.

Purpose of the Study:

• To review mechanisms of acquired resistance to EGFR TKIs, including third-generation inhibitors.
• To introduce EAI045, a novel allosteric EGFR inhibitor designed to overcome resistance.
• To discuss the potential of EAI045 as a fourth-generation EGFR inhibitor.

Main Methods:

• Review of recent scientific literature on EGFR TKI resistance mechanisms.
• Summary of preclinical investigations into the efficacy of EAI045.
• Analysis of resistance mutations such as EGFR C797S and amplifications of HER2, MET, or ERBB2.

Main Results:

• Resistance to third-generation EGFR TKIs emerges through various genetic alterations.
• EAI045 demonstrates efficacy against EGFR mutations conferring resistance, including T790M and C797S.
• EAI045 represents a potential therapeutic strategy against resistant NSCLC.

Conclusions:

• Understanding EGFR TKI resistance mechanisms is crucial for developing next-generation therapies.
• EAI045 shows significant potential as a fourth-generation EGFR inhibitor to overcome acquired resistance.
• Further clinical investigation of EAI045 is warranted for NSCLC patients with acquired resistance.